This trial is evaluating whether Treatment will improve 1 primary outcome and 15 secondary outcomes in patients with Hemorrhagic Stroke. Measurement will happen over the course of 12 months post-stroke.
This trial requires 1800 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"Stroke refers to a focal impairment of brain function from a cerebral blood flow constraint that originates in the brain or is the result of an embolic event. Stroke is usually the result of a large vessel infarct, which are typically located on the right side of the body due to the heart being on the left. Strokes are often classified by either being ischaemic (due to occlusion of a blood vessel) or haemorrhagic (due to leakage from a blood vessel) and they cause serious disability. Stroke commonly affects the blood vessels supplying the brain causing the blood vessels to become narrowed and constricted. The arteries that supply the brain are called intracranial blood vessels." - Anonymous Online Contributor
"Stroke can be divided into reversible and nonreversible syndromes. Reversible stroke is amenable to treatment and complete neurologic recovery can occur. Patients who experience nonreversible strokes remain chronically impaired and can benefit from rehabilitation, which significantly improves the quality of life for most patients." - Anonymous Online Contributor
"The most commonly used treatment is surgery, with other treatments including medication, other medical care, physical therapy, and occupational therapy. The quality of research on which treatments are most effective is poor, and many treatments have not been scientifically studied adequately. Also, the quality of stroke data collection is poor." - Anonymous Online Contributor
"Genetic factors account for a significant proportion of the risk of stroke, and lifestyle factors are also important. Many stroke risk factors appear to have common genetic or environmental pathways. Risk factors that affect blood pressure and blood lipids show a stronger association with stroke than those of smoking or obesity." - Anonymous Online Contributor
"The majority (95%) of people presenting to an acute stroke unit have some evidence of stroke. About half of these individuals (41%) have transient ischaemic attacks (TIAs) or acute transient focal cerebral ischaemic events (TFCIEs). Although there is substantial overlap between the signs and symptoms of stroke and the signs of TIAs and TFCIEs, these may serve as important clinical signposts highlighting TIA/stroke as a continuum of conditions with common risk factors. The presence of sensory loss, new motor and sensory deficits and speech and language disturbance are signs of stroke." - Anonymous Online Contributor
"Approximately 430,700 Americans have a stroke each year, making up around 9% of all American adults. These strokes cause around 78,000 deaths each year and result in long-term disability for almost one-third of these patients." - Anonymous Online Contributor
"All of the measures related to life impact after stroke had significant correlations with the measure of quality of life. The patients' quality of life was significantly less the more they had to be bedridden. The degree of dependence and pain after stroke appeared to correlate with their quality of life." - Anonymous Online Contributor
"For the treatment to be effective, it should produce a statistically significant difference from the baseline to the post-treatment group and it had to be higher in the treatment group compared to the control group and to the baseline. This should reflect a good improvement on the scale. Thus, to summarize these results, an improvement between 10% and 15% of the value at the end of 4 weeks was considered to be a significant difference. From a meta-analysis of 14 trials, we can conclude that stroke management and quality of life of patients in the two groups does not present a statistically significant difference on the 4-week period." - Anonymous Online Contributor
"The mean age at stroke incidence is 73 years old for all stroke subtypes and for both male and female stroke sufferers. This information is important for stroke education and should be reported to aid stroke prevention strategies." - Anonymous Online Contributor
"Most patients with a minor stroke seem to benefit from current treatments for strokes. Some patients' early stroke symptoms seem to resolve when they are treated with aspirin, and most patients seem satisfied with treatment. However, many patients are not monitored and a minority does not realize their strokes are unlikely to worsen. In light of these findings, it is imperative that healthcare providers ensure patients understand the steps needed for follow-up visits in the event of a relapse. Patients can also benefit from being informed of the risk of having a major stroke." - Anonymous Online Contributor
"The data we obtained were similar to those from other studies. In a previous study, this study was one of the largest cohorts to have been used in a systematic review to assess the treatment of vascular patients; as such it represents a 'gold standard' comparison." - Anonymous Online Contributor
"There is little evidence that intravenous thrombolysis improves neurological outcome in patients with acute stroke beyond that seen in this trial. While the benefit of intravenous thrombolysis is well established, treatment rates remain low in acute stroke, suggesting that increased public awareness of and improved access to acute stroke treatment may be more effective than further research on intravenous thrombolysis. We suggest that further studies with wider sample sizes of patients would be useful in confirming that intravenous thrombolysis is an effective treatment of acute stroke." - Anonymous Online Contributor